Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage II or III (T2-4a, Nx or N0, M0) primary carcinoma of the bladder with muscle invasion~  * Resectable disease~ * Prostatic urethral involvement with transitional cell carcinoma allowed, if completely resected and no evidence of stromal invasion~ * No tumor-related hydronephrosis~* Positive lymph node must be evaluated by lymphadenectomy or percutaneous needle biopsy~  * No nodal metastases~* No distant metastases~* No more than 6 weeks since prior transurethral resection of the bladder tumor~  * Functioning bladder~PATIENT CHARACTERISTICS:~Age:~* Adult~Performance status:~* Zubrod 0-1~Life expectancy:~* Not specified~Hematopoietic:~* Hemoglobin at least 10 g/dL~* White blood cell (WBC) count of at least 4,000/mm\^3~* Absolute neutrophil count at least 1,800/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.0 mg/dL~Renal:~* Creatinine no greater than 1.5 mg/dL~* Creatinine clearance at least 60 mL/min~Other:~* No other prior or concurrent malignancy within the past 5 years except curatively treated nonmelanoma skin cancer, stage I prostate cancer, or carcinoma in situ of the cervix~* Not pregnant~* Negative pregnancy test~* Fertile patients must use effective contraception~* Medically operable~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior systemic chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior pelvic radiotherapy~Surgery:~* See Disease Characteristics~Other:~* No concurrent potential nephrotoxic or ototoxic drugs (e.g., aminoglycosides)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Transurethral surgery with chemotherapy and radiation therapy followed by either selective bladder preservation or radical cystectomy followed by adjuvant chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).